Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical Diagnostics
O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.
Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharma
A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.
Getting on Board with Diversity: Behind the Push for More Gender Representation
States and institutions are enacting mandates requiring greater inclusion of women and underrepresented groups on corporate boards; what are the key questions for pharma?
A New Mindset on Innovation: At This Rate, Big Pharma May Need a Bigger Sandbox
Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value.
2 Commerce Drive Cranbury, NJ 08512